One of the nice things about OPIG, is that you can talk about something which is outside of your wheelhouse without feeling that the specialists in the group are going to eat your lunch. Last week, I gave an overview of the Hubbell group‘s Nature paper Synthetically glycosylated antigens for the antigen-specific suppression of established immune responses. I am not an immunologist by any stretch of the imagination, but sometimes you come across a piece of really interesting science and just want to say to people: Have you seen this, look at this, it’s really clever!
Continue readingCategory Archives: Group Meetings
Thera-SAbDab Updates (2023)
This blogpost is a short notice about recent quality-of-life and feature updates to our Therapeutic Structural Antibody Database (Thera-SAbDab). We hope these changes will make the database more user-friendly and facilitate new analyses…
Continue readingOut of Band Management
We’ve all had things go wrong with computers, however when they go catastrophically wrong, there’s often little you can do other than to be physically on site to reinstall. This doesn’t have to be the case though. Most PCs have a tiny secondary processor which can allow full remote control of a computer that’s crashed, unresponsive or even switched off.
Continue readingOPIG Retreat 2023
With the new academic year approaching, OPIG flew off to the rural paradise of Wilderhope Manor in sunny Shropshire for their annual group getaway. The goal of this retreat was assumed to be a mixture of team building, ‘conference-esque’ academic immersion, a reconnection with nature in the British countryside, and of course, a bit of fun. It is fair to say OPIG Retreat ‘23 delivered on all accounts, leaving the OPIGlets refreshed and ready for what the next year may bring.
Continue readingWhat can you do with the OPIG Immunoinformatics Suite? v3.0
OPIG’s growing immunoinformatics team continues to develop and openly distribute a wide variety of databases and software packages for antibody/nanobody/T-cell receptor analysis. Below is a summary of all the latest updates (follows on from v1.0 and v2.0).
Continue readingExperience at a Keystone Symposium
From 19th-22nd February I was fortunate enough to participate in the joint Keystone Symposium on Next-Generation Antibody Therapeutics and Multispecific Immune Cell Engagers, held in Banff, Canada. Now in their 51st year, the Keystone Symposia are a comprehensive programme of scientific conferences spanning the full range of topics relating to human health, from studies on fundamental bodily processes through to drug discovery.
Continue readingLaTeX Beamer Template with Logos
Alternative Title: The tragic story of how I got trapped making slides with latex.
Typically after giving a presentation at least one person will approach me and ask if they could have access to my custom latex template to make slides with beamer that don’t look rubbish.
TL;DR Yes you can: https://github.com/npqst/latex-beamer-template
Continue readinghisto.fyi: A Useful New Database of Peptide:Major Histocompatibility Complex (pMHC) Structures
pMHCs are set to become a major target class in drug discovery; unusual peptide fragments presented by MHC can be used to distinguish infected/cancerous cells from healthy cells more precisely than over-expressed biomarkers. In this blog post, I will highlight a prototype resource: Dr. Chris Thorpe’s new database of pMHC structures, histo.fyi.
histo.fyi provides a one-stop shop for data on (currently) around 1400 pMHC complexes. Similar to our dedicated databases for antibody/nanobody structures (SAbDab) and T-cell receptor (TCR) structures (STCRDab), histo.fyi will scrape the PDB on a weekly basis for any new pMHC data and process these structures in a way that facilitates their analysis.
Continue readingAn evolutionary lens for understanding cancer and its treatment
I recently found myself in the Oxford Blackwells’ Norrington Room browsing the shelves for some holiday reading. One book in particular caught my eye, a blend of evolution — a topic that has long interested me — and cancer biology, a topic I’m increasingly exposed to in immune repertoire analysis collaborations but on which I am assuredly “non-expert”!
The Cheating Cell by Athene Aktipis provides a theoretical framework for understanding cancer by considering it as a logical sequitor of the advent of successful multicellular life.
Continue readingMonoclonal antibody PRNP100 therapy for Creutzfeldt–Jakob disease
Recently, University College London Hospitals (UCLH) received a “Specials License” to allow the treatment of six patients suffering from Creutzfeldt–Jakob Disease (CJD), by way of a novel antibody known as PRN100. The results of this treatment have now been published in The Lancet.
There is currently no cure for CJD, yet over 100 people per year develop it either spontaneously or through external means including (but not limited to) growth hormones, cataract surgery or infected neurosurgical implements [1]. “There is no UK legislation which implements a compassionate use programme as set out in Article 83 of the relevant EU regulation. But the UK has implemented an exemption process known as the “Specials” in light of the requirement to be able to deal with special needs.” [2]
As there is no known cure, the request for use of PRN100 was put before the court as in Law “Some treatment decisions are so serious that the court has to make them.”
Continue reading